Redeye shares its initial take on Physitrack’s Q1 2025 results.
Redeye provides a brief comment on the latest expansion of the Digital Extremes development agreemen...
Q1 profit before loan losses came in at DKK 56m, DKK 3m (6%) above our estimate.
'25e-'27e adj. EBITA down 3% Already strong gross margin in Q1 can turn even stronger in H2 ~9x '25e...
Sales -7% (EEs -9%, SCs +15%), EBIT -19% vs. our estimates Opex in line, low equipment sales only a ...
Beijer Alma levererar en bra kvartalsrapport som visar på både organisk och förvärvsdriven tillväxt ...
Gapwaves reported a robust quarter, with net sales up 46% y/y, meeting consensus but falling 9% shor...
Egetis delivered sales along expectations and more importantly, the German launch is underway follow...
'25e sales cut by 5%, three system deliveries for '25e (prev.
Redeye provides an update of its estimates and valuation for Serstech following the Q1 2025 report a...
Redeye updates its estimates and valuation following MedCap releasing its Q1 2025 report.
Q1: Sales 4% below, EBITDA NOK 10m vs ABGSCe of NOK 4m Lower target range likely EBIT estimates larg...
Strong Q1 with operational leverage driving margin expansion Adj.
Acceleration across segments - organic momentum improved Another (self-funded) Thebalux-size acquisi...
Redeye retains its positive view of Sdiptech following a stable Q1 report.
